2 low-priced gene therapy stocks to speculate on

Key Pointsbluebird bio has three FDA-approved gene therapy treatments that are planning to commercialize after its $150 million secondary offering of common shares priced at $1.50 per share.bluebird bio's latest FDA approval, LYFGENIA, is a one-time treatment for sickle cell disease, which is priced around $3.1 million per patient, which is 40% higher than Vertex Pharmaceutical's Casgevy at $2.1 million, which was approved on same day Dec. 8, 2023.Sangamo Therapeutics has paused further investment into two ...